PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs

• Published in: Cells (Basel, Switzerland) Vol. 10; no. 7; p. 1679
• Main Authors: Lypova, Nadiia, Dougherty, Susan M., Lanceta, Lilibeth, Chesney, Jason, Imbert-Fernandez, Yoannis
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 03-07-2021; MDPI
• Subjects: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3); Antibodies; Autophagy; autophagy flux; Cancer therapies; Cell growth; Chemotherapy; cytoprotective autophagy; Cytotoxicity; Epidermal growth factor; epidermal growth factor receptor (EGFR); Epidermal growth factor receptors; Experiments; Glycolysis; Kinases; lung cancer; Lung carcinoma; Mutation; Non-small cell lung carcinoma; Phagocytosis; Protein-tyrosine kinase; Proteins; Small cell lung carcinoma; Tumors; United States > US
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells10071679

Tyrosine kinase inhibitors (TKIs) targeting the kinase domain of the epidermal growth factor receptor (EGFR), such as erlotinib, have dramatically improved clinical outcomes of patients with EGFR-driven non-small cell lung carcinomas (NSCLCs). However, intrinsic or acquired resistance remains a clinical barrier to the success of FDA-approved EGFR TKIs. Multiple mechanisms of resistance have been identified, including the activation of prosurvival autophagy. We have previously shown that the expression and activity of PFKFB3—a known driver of glycolysis—is associated with resistance to erlotinib and that PFKFB3 inhibition improves the response of NSCLC cells to erlotinib. This study focuses on investigating the role of PFKFB3 in regulating erlotinib-driven autophagy to escape resistance to erlotinib. We evaluated the consequence of pharmacological inhibition of PFKFB3 on erlotinib-driven autophagy in NSCLC cells with different mutation statuses. Here, we identify PFKFB3 as a mediator of erlotinib-induced autophagy in NSCLCs. We demonstrate that PFKFB3 inhibition sensitizes NCSLCs to erlotinib via impairing autophagy flux. In summary, our studies uncovered a novel crosstalk between PFKFB3 and EGFR that regulates erlotinib-induced autophagy, thus contributing to erlotinib sensitivity in NSCLCs.